CHRS: Coherus BioSciences, Inc.
About
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Current Value
$0.821 Year Return
Current Value
$0.821 Year Return
Key Details
Market Cap
$94.65M
P/E Ratio
-8.16
1Y Stock Return
-58.72%
1Y Revenue Growth
44.19%
Dividend Yield
0.00%
Price to Book
-1.1
Strategies that include CHRS
Stock's related to CHRS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TWST | 44.41% | $2.42B | +74.27% | 0.00% |
| ATSG | 41.60% | $1.44B | +39.23% | 0.00% |
| WSM | 40.90% | $17.34B | +52.54% | 1.84% |
| PLRX | 39.94% | $778.32M | -9.55% | 0.00% |
| WRBY | 39.79% | $2.75B | +120.67% | 0.00% |
| BIGC | 39.60% | $473.42M | -31.75% | 0.00% |
| OLO | 39.47% | $1.06B | +30.00% | 0.00% |
| NVCR | 39.24% | $1.78B | +34.75% | 0.00% |
| GLDD | 38.05% | $828.12M | +90.26% | 0.00% |
| ALLO | 38.03% | $444.50M | -24.82% | 0.00% |
| VPG | 37.95% | $279.20M | -30.23% | 0.00% |
| FOLD | 37.11% | $2.84B | -11.52% | 0.00% |
| KC | 36.90% | $1.16B | -4.97% | 0.00% |
| HOUS | 36.71% | $459.51M | -15.54% | 0.00% |
| MGTX | 36.63% | $467.36M | +9.12% | 0.00% |
| RCUS | 36.38% | $1.33B | +5.07% | 0.00% |
| PGEN | 36.29% | $228.91M | -28.00% | 0.00% |
| LAW | 36.03% | $325.90M | -3.37% | 0.00% |
| NXDT | 35.34% | $218.01M | -37.42% | 11.58% |
| LIND | 35.22% | $722.18M | +75.26% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| REYN | -0.01% | $5.79B | +3.76% | 3.35% |
| CME | 0.05% | $82.76B | +9.21% | 1.98% |
| AMED | -0.13% | $2.95B | -3.95% | 0.00% |
| KHC | -0.14% | $36.98B | -10.45% | 5.23% |
| TW | -0.16% | $28.66B | +42.39% | 0.29% |
| FENG | -0.19% | $13.37M | +96.77% | 0.00% |
| HRB | 0.21% | $7.59B | +20.02% | 2.42% |
| CLX | 0.37% | $20.81B | +20.66% | 2.88% |
| KR | 0.37% | $42.03B | +35.08% | 2.11% |
| RSG | -0.43% | $66.05B | +31.79% | 1.04% |
| OXBR | 0.44% | $19.05M | +178.18% | 0.00% |
| GAN | -0.46% | $83.39M | +21.19% | 0.00% |
| AJG | -0.58% | $64.17B | +17.51% | 0.80% |
| VZ | 0.62% | $176.51B | +12.56% | 6.37% |
| WM | -0.73% | $87.92B | +27.58% | 1.34% |
| RYAN | 0.76% | $8.81B | +55.63% | 0.62% |
| CHE | 0.77% | $8.20B | -5.60% | 0.33% |
| HUSA | 0.77% | $16.69M | -11.56% | 0.00% |
| ORLY | 0.80% | $69.31B | +22.06% | 0.00% |
| FCN | -0.84% | $7.10B | -10.74% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| COR | -16.01% | $47.48B | +21.20% | 0.86% |
| KRRO | -13.22% | $436.84M | +20.68% | 0.00% |
| RNR | -11.91% | $13.74B | +23.09% | 0.58% |
| MCK | -11.05% | $78.15B | +35.51% | 0.42% |
| CHD | -10.96% | $27.18B | +19.50% | 1.03% |
| PGR | -10.29% | $149.10B | +57.29% | 0.45% |
| BACK | -9.97% | $1.76M | -32.90% | 0.00% |
| IEP | -9.36% | $5.70B | -31.12% | 31.39% |
| TCTM | -9.04% | $8.10M | -42.99% | 0.00% |
| MNR | -7.55% | $1.66B | -10.71% | 15.90% |
| IMNN | -7.51% | $10.02M | -22.89% | 0.00% |
| SOC | -6.99% | $1.93B | +74.70% | 0.00% |
| HIHO | -6.24% | $8.63M | 0.00% | 6.12% |
| PULM | -6.07% | $19.83M | +202.98% | 0.00% |
| CBOE | -5.25% | $21.46B | +15.84% | 1.11% |
| LPTH | -4.78% | $62.27M | +33.05% | 0.00% |
| TGT | -4.74% | $71.87B | +19.27% | 2.59% |
| GIS | -4.66% | $34.85B | -2.91% | 3.78% |
| APRE | -4.62% | $16.41M | -19.47% | 0.00% |
| ALL | -4.62% | $52.06B | +45.67% | 1.85% |
ETF's related to CHRS
News
Yahoo
Q3 2024 Coherus BioSciences Inc Earnings Call
Yahoo
Coherus BioSciences Inc (CHRS) reports significant revenue growth and market share gains, despite facing supply interruptions impacting future sales projections.
SeekingAlpha
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ETCompany ParticipantsJodi Sievers - Head of Investor...
Yahoo
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 90% and 24.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
REDWOOD CITY, Calif. AP) — Coherus BioSciences Inc. CHRS) on Wednesday reported a loss of $10.8 million in its third quarter.
Yahoo
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract manufacturing organization – – LOQTORZI® launch progressing to plan, revenues increase 50% quarter-over-quarter – – Innovative immuno-oncology pipeline advancing to proof-of-concept studies in combination with toripalimab – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Nov. 06, 202
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.